Hunan Jiudian Pharmaceutical Co., Ltd.

300705

CNE1000034Z6

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
37.36 ^CNY	+1.49%		+3.52%	+12.43%

Apr. 25	Hunan Jiudian Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023	CI
Apr. 24	Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Nan Jiudian Pharmaceutical Announces Profit Distribution Plan for 2021

April 27, 2022 at 03:36 pm EDT

Hunan Jiudian Pharmaceutical Co., Ltd. proposed cash dividend/10 shares (tax included) of CNY 2.61000000 for the year 2021.

Latest news about Hunan Jiudian Pharmaceutical Co., Ltd.

Hunan Jiudian Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023	Apr. 24	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Elects Yang Yang and Fan Pengyun as Non-Independent Director	Jan. 26	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-23	CI
Hunan Jiudian Pharmaceutical Co., Ltd.(XSEC:300705) added to S&P Global BMI Index	23-09-18	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-15	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Approves 2022 Final Profit Distribution, Payable on May 15, 2023	23-05-09	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Proposes Cash Dividend for the Year of 2022	23-04-17	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Hunan Jiudian Pharma Wins Nod to Trial Anti-Inflammatory Patch	23-04-05	MT
Jiudian Pharma Sees FY22 Profit to Rise Up to 33.7%	23-01-16	MT
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-07-29	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 27 May 2022	22-05-20	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021	22-05-18	CI
Nan Jiudian Pharmaceutical Announces Profit Distribution Plan for 2021	22-04-27	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-26	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-25	CI
Hunan Jiudian Pharmaceutical Co., Ltd. entered into an agreement to acquire Hunan Huiyang Information Technology Co., Ltd. from Duan Lixin and Duan Linong for CNY 8.56 million.	21-08-09	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-09	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Approves Final Dividend for the Year 2020	21-05-10	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Announces Earnings Results for the First Quarter Ended March 31, 2021	21-04-28	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2020	21-04-19	CI

Chart Hunan Jiudian Pharmaceutical Co., Ltd.

Duration

Period

Chart Hunan Jiudian Pharmaceutical Co., Ltd.

More charts

Hunan Jiudian Pharmaceutical Co Ltd is a company mainly engaged in research and development, production and sales of pharmaceutical preparations. The Companyâs products are comprised of pharmaceutical preparations, raw materials, pharmaceutical excipients and plant extracts, including loxoprofen sodium gel ointment, ornidazole raw materials and preparations, dirithromycin raw materials and preparations, clindamycin phosphate tablets and so on. The products are used for the treatment of bacterial infections and anti-allergy. The Company sells its products to both domestic and international markets, including Europe, South Korea, India, Russia and South America.

Sector

Pharmaceuticals

Calendar

2024-05-15 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Hunan Jiudian Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

37.36

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HUNAN JIUDIAN PHARMACEUTICAL CO., LTD.	+12.43%	1.78B
ELI LILLY AND COMPANY	+33.25%	704B
NOVO NORDISK A/S	+28.59%	577B
JOHNSON & JOHNSON	-3.55%	348B
MERCK & CO., INC.	+18.16%	327B
ABBVIE INC.	+4.36%	288B
ASTRAZENECA PLC	+14.81%	234B
NOVARTIS AG	+4.93%	198B
ROCHE HOLDING AG	-9.78%	194B
AMGEN INC.	-3.69%	147B

Other Pharmaceuticals

Hunan Jiudian Pharmaceutical Co., Ltd.

Equities

300705

CNE1000034Z6

Pharmaceuticals

Nan Jiudian Pharmaceutical Announces Profit Distribution Plan for 2021

Latest news about Hunan Jiudian Pharmaceutical Co., Ltd.

Chart Hunan Jiudian Pharmaceutical Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Hunan Jiudian Pharmaceutical Co., Ltd.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals